MOUNJARO Diabetes Medicine at Eli Lilly, will be available in the Brazilian market from the day June 7 . The information was confirmed on Wednesday (20) by the pharmacist CNN . Check below for whom the drug is indicated and how much it should cost in the country.
Considered the main competitor of Ozempic and Wegovy, both of the New Danish Pharmacist Nordisk, the drug is composed of thiepatit, a double agonist molecule of GLP-1 and GIP, hormones generated in the intestine and released after meals, increasing insulin production by the pancreas to maintain blood sugar control.
What is the differential of Mounjaro and who is indicated for?
Mounjaro was approved by the National Health Surveillance Agency (Anvisa) in Brazil in September 2023 for the treatment of type 2 diabetes.
“There are already other medicines in Brazil of the same class, but Mounjaro has a different mechanism of action, because it is not just an agonist, that is, it does not only act on the GLP-1 receiver, it also acts on the GIP receiver. It is the only medicine of this class that acts on these two receptors,” explains Luiz Magno, senior medical director of Eli Lilly do Brasil, to CNN .
The drug should be used to treat diabetes associated with lifestyle changes, such as the adoption of healthy eating and the practice of physical activity.
In a clinical test, Mounjaro led to control of blood glucose in 92% of 15 mg drug -treated patients – they managed to get a glycated hemoglobin below 7%, which is the level recommended by medical guidelines for proper diabetes control.
“This is a very important number,” says Magno. “We know that in Brazil we have a gigantic population with diabetes, there are more than 16 million people. Of these, 90% have type 2 diabetes and are obese or overweight,” he adds.
Mounjaro leads to weight loss higher than Wegovy
In recent studies, Mounjaro promoted a relative weight loss 47% higher than WeGovy, by the Novo Nordisk pharmacist, according to data from a new clinical study announced in December.
According to the work, the tirzepatida led to a weight loss of 20.2%, higher when compared to 13.7% of semaglutado (compound present in Wegovy and also in Ozempic). After 72 weeks of the study, the Mounjaro was higher than the semaglutide in the primary outcome and in all five main secondary outcomes of the study.
Despite that, The approval of the drug by Anvisa only includes the treatment of type 2 diabetes And, therefore, The use for treatment of obesity is not yet approved .
“Today, in Brazil, the indication approved by Anvisa is for type 2 diabetes. So, at this moment, we are only talking about weight loss in the diabetic patient,” says Magno.
The medical director states that Eli Lilly has already submitted to Anvisa to indicate the tirzepatida for the treatment of obesity. The request is under analysis.
How much will Mounjaro cost in Brazil?
According to the Medicines Market Regulation Chamber (CMED), which defines the maximum price to the consumer (authorized price at trade in a drug).
The value of the Mounjaro may vary depending on the tax on goods circulation and services (ICMS) in each state, dose and the amount of pens for application per packaging. For example, in São Paulo, the maximum dose may cost R $ 3,791.07.
Mounjaro reduces risk of pre-diabetes to become diabetes by 94%
This content was originally published in Mounjaro: for whom the medicine is indicated and how much it will cost on CNN Brazil.
Source: CNN Brasil
I am an experienced journalist and writer with a career in the news industry. My focus is on covering Top News stories for World Stock Market, where I provide comprehensive analysis and commentary on markets around the world. I have expertise in writing both long-form articles and shorter pieces that deliver timely, relevant updates to readers.
